Acadia Pharmaceuticals Inc (ACAD) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Acadia Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 27.51 at 8:15 am ET, low 26.87 at 4:00 pm ET.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
the bull case· 3
6
disclosed supplier and customer ties in SEC filings
sec filingsedgar350
managers reporting a position in the latest quarterly filings
13fJun 30 '26+3.27%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4
of the funds on file reporting a position in ACAD
n-portas of Jun 30 '260.94%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '268 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 4 '26 report. Not a forecast, not advice.
Of the 6 companies Acadia Pharmaceuticals Inc moves with most closely, none share its SEC classification.
Measured against 139 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
350 managers report a position worth $4.3B between them, and 26 of them hold 80% of it.
tall tick = annual report · 1 on record
ACAD (Acadia Pharmaceuticals Inc) has 2 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.